AU2014359409A1 - Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof - Google Patents

Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof Download PDF

Info

Publication number
AU2014359409A1
AU2014359409A1 AU2014359409A AU2014359409A AU2014359409A1 AU 2014359409 A1 AU2014359409 A1 AU 2014359409A1 AU 2014359409 A AU2014359409 A AU 2014359409A AU 2014359409 A AU2014359409 A AU 2014359409A AU 2014359409 A1 AU2014359409 A1 AU 2014359409A1
Authority
AU
Australia
Prior art keywords
compound
formula
certain embodiment
relates
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014359409A
Other languages
English (en)
Inventor
Jean-Michel Adam
Bjoern Bartels
Ralph Diodone
Olaf Grassmann
Thomas Hartung
Fabienne Hoffmann-Emery
Christophe Pfleger
Frederic Ran
Benno Rothenhaeusler
Urs Schwitter
Rene Trussardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2014359409A1 publication Critical patent/AU2014359409A1/en
Priority to AU2019201183A priority Critical patent/AU2019201183B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2014359409A 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof Abandoned AU2014359409A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201183A AU2019201183B2 (en) 2013-12-05 2019-02-20 Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13195864 2013-12-05
EP13195864.7 2013-12-05
PCT/EP2014/076041 WO2015082370A1 (en) 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201183A Division AU2019201183B2 (en) 2013-12-05 2019-02-20 Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Publications (1)

Publication Number Publication Date
AU2014359409A1 true AU2014359409A1 (en) 2016-05-19

Family

ID=49726573

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014359409A Abandoned AU2014359409A1 (en) 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
AU2019201183A Active AU2019201183B2 (en) 2013-12-05 2019-02-20 Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201183A Active AU2019201183B2 (en) 2013-12-05 2019-02-20 Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Country Status (19)

Country Link
US (3) US10246460B2 (OSRAM)
EP (1) EP3077396B1 (OSRAM)
JP (1) JP6454707B2 (OSRAM)
KR (3) KR102384629B1 (OSRAM)
CN (1) CN105793263B (OSRAM)
AR (1) AR098592A1 (OSRAM)
AU (2) AU2014359409A1 (OSRAM)
CA (2) CA3142754C (OSRAM)
ES (1) ES2875411T3 (OSRAM)
HR (1) HRP20210966T1 (OSRAM)
IL (2) IL245450A0 (OSRAM)
MX (1) MX372971B (OSRAM)
MY (1) MY175464A (OSRAM)
NZ (1) NZ720340A (OSRAM)
PL (1) PL3077396T3 (OSRAM)
SG (1) SG11201604502SA (OSRAM)
SI (1) SI3077396T1 (OSRAM)
WO (1) WO2015082370A1 (OSRAM)
ZA (1) ZA201603304B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210966T1 (hr) 2013-12-05 2021-09-17 F. Hoffmann - La Roche Ag Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraaza­benzo[e]azulena i njegovih kristalnih oblika
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
TWI816718B (zh) 2017-12-08 2023-10-01 瑞士商赫孚孟拉羅股份公司 醫藥調配物
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
US20240154207A1 (en) 2021-10-06 2024-05-09 Lg Energy Solution, Ltd. Battery module

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
DE602004003914T2 (de) * 2003-02-19 2007-05-31 Pfizer Inc. Für die therapie geeignete triazolverbindungen
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
WO2006021882A1 (en) 2004-08-25 2006-03-02 Pfizer Limited Triazolobenzodiazepines and their use as vasopressin antagonists
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
KR101385433B1 (ko) * 2008-11-18 2014-04-14 에프. 호프만-라 로슈 아게 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터
DK2370441T3 (da) * 2008-11-28 2013-10-21 Hoffmann La Roche Arylcyclohexylethere af dihydrotetraazabenzoazulener til anvendelse som vasopressin v1a-receptorantagonister
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
CN105492010B (zh) 2013-08-19 2020-01-03 豪夫迈·罗氏有限公司 用于治疗相移睡眠障碍的V1a拮抗剂
HRP20210966T1 (hr) * 2013-12-05 2021-09-17 F. Hoffmann - La Roche Ag Sinteza trans-8-kloro-5-metil-1-[4-(piridin-2-iloksi)-cikloheksil]-5,6-dihidro-4h-2,3,5,10b-tetraaza­benzo[e]azulena i njegovih kristalnih oblika

Also Published As

Publication number Publication date
EP3077396A1 (en) 2016-10-12
NZ720340A (en) 2020-03-27
CA3142754C (en) 2024-01-02
MX372971B (es) 2020-03-27
SG11201604502SA (en) 2016-07-28
MY175464A (en) 2020-06-29
US20190194210A1 (en) 2019-06-27
RU2018135601A3 (OSRAM) 2022-05-05
CA2931016A1 (en) 2015-06-11
IL264891B (en) 2021-02-28
MX2016006558A (es) 2016-08-03
KR102384630B1 (ko) 2022-04-11
CA3142754A1 (en) 2015-06-11
KR20210134985A (ko) 2021-11-11
NZ759478A (en) 2021-06-25
ES2875411T3 (es) 2021-11-10
US12459947B2 (en) 2025-11-04
US20160280712A1 (en) 2016-09-29
ZA201603304B (en) 2022-05-25
US10246460B2 (en) 2019-04-02
US20210284648A1 (en) 2021-09-16
RU2018135601A (ru) 2018-11-22
AU2019201183B2 (en) 2021-03-04
CN105793263A (zh) 2016-07-20
KR20160093709A (ko) 2016-08-08
KR102384629B1 (ko) 2022-04-11
US11040977B2 (en) 2021-06-22
AU2019201183A1 (en) 2019-03-14
JP6454707B2 (ja) 2019-01-16
HRP20210966T1 (hr) 2021-09-17
KR20210132745A (ko) 2021-11-04
WO2015082370A1 (en) 2015-06-11
AR098592A1 (es) 2016-06-01
CN105793263B (zh) 2019-08-23
JP2016539168A (ja) 2016-12-15
CA2931016C (en) 2022-11-01
IL245450A0 (en) 2016-06-30
HK1223918A1 (zh) 2017-08-11
PL3077396T3 (pl) 2021-10-04
EP3077396B1 (en) 2021-04-21
KR102384608B1 (ko) 2022-04-08
SI3077396T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
AU2019201183B2 (en) Synthesis of trans-8-chloro-5-methyl-1 -[4-(Pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4H-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof
EP3271018B1 (en) Processes and intermediates for the preparation of pimavanserin
CN105008325B (zh) 光学活性二胺化合物的制备方法
AU2018308038B2 (en) Improved process for preparing aminopyrimidine derivatives
AU2021389180A1 (en) Heteroaryl carboxamide compound
AU2011278998A1 (en) Therapeutically active compositions and their method of use
JP2013532164A (ja) トロンビン特異的インヒビターを調製する方法
EP2346850A1 (en) A method for the preparation of dabigatran and its intermediates
JP2014097981A (ja) 2−アミノ−n−(2,2,2−トリフルオロエチル)アセトアミド化合物又はその塩の製造方法
WO2014020555A2 (en) An improved process for the preparation of dabigatran etexilate mesylate
KR20230004622A (ko) 모노아실글리세롤 리파제 억제제의 합성
EP3658569B1 (en) Process and intermediates for synthesis of peptide compounds
RU2775690C2 (ru) Синтез транс-8-хлор-5-метил-1-[4-(пиридин-2-илокси)-циклогексил]-5,6-дигидро-4н-2,3,5,10в-тетраазабензо[e]азулена и его кристаллические формы
NZ759478B2 (en) Synthesis of trans-8-chloro-5-methyl-1-[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof
AU2005269634A1 (en) Synthesis of 6,7-dihydro-5H-imidazo(1,2-a)imidazole-3-sulfonic acid amides
CN120289428A (zh) 一种1-氧代异吲哚啉衍生物及其应用
Zhang et al. A facile and efficient synthesis of d3‐labelled Reyataz™
CA2610059A1 (en) 1-hydroxycycloalkanecarboxamide derivatives as bradykinin antagonists
HK1223918B (zh) 一种苯并[e]薁化合物及其晶型的合成
WO2010092286A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted